| abstract |
The present invention relates to compounds of formula (I), or pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof: Formula I Where A is ego; Ar 1 is aryl or 6 membered heteroaryl; Ar 2 is aryl or 6 membered heteroaryl; R 1 is hydrogen, halogen, lower alkyl, lower alkoxy, or lower alkyl substituted with halogen; R 2 is hydrogen, halogen, lower alkyl, lower alkyl or cyano substituted with halogen; R 3 is hydrogen or lower alkyl; R 4 is hydrogen, lower alkyl, phenyl optionally substituted with halogen, 5-membered heteroaryl optionally substituted with lower alkyl, or aryl optionally substituted with halogen; Is a 6 membered heterocyclic group; X is -N (SO 2 CH 3 ); R 6 is hydrogen; Y is -N (R 7 ' )-; R 7 ′ is 6-membered heteroaryl unsubstituted or substituted with cyano or C (O) -cycloalkyl, wherein the cycloalkyl group is optionally substituted by lower alkyl; n is 1; m is 1; o is 1; p is 1; s is 0; t is 1; u is one. The compounds of the present invention have been found to be very useful NK3 receptor antagonists in the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD). |